ALEC: Alector, Inc.
About
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Current Value
$3.841 Year Return
Current Value
$3.841 Year Return
Key Details
Market Cap
$377.04M
P/E Ratio
-2.25
1Y Stock Return
-19.46%
1Y Revenue Growth
-36.14%
Dividend Yield
0.00%
Price to Book
3.2
Strategies that include ALEC
Stock's related to ALEC
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DNLI | 55.72% | $3.50B | +33.66% | 0.00% |
| NTLA | 52.65% | $1.44B | -50.35% | 0.00% |
| RCKT | 52.40% | $1.20B | -39.83% | 0.00% |
| BEAM | 51.69% | $2.09B | -9.52% | 0.00% |
| IDYA | 47.29% | $2.24B | -15.21% | 0.00% |
| EDIT | 47.19% | $204.72M | -75.49% | 0.00% |
| RCUS | 46.96% | $1.33B | +5.07% | 0.00% |
| ACLX | 46.72% | $4.74B | +69.19% | 0.00% |
| PGEN | 46.63% | $228.91M | -28.00% | 0.00% |
| CRBU | 46.55% | $180.20M | -62.45% | 0.00% |
| CRSP | 46.03% | $4.01B | -30.49% | 0.00% |
| PSTX | 45.86% | $269.98M | +6.13% | 0.00% |
| PRTA | 45.43% | $756.01M | -56.52% | 0.00% |
| PLRX | 45.13% | $778.32M | -9.55% | 0.00% |
| RGNX | 44.95% | $473.65M | -51.96% | 0.00% |
| RXRX | 44.92% | $1.80B | -4.13% | 0.00% |
| SNDX | 44.82% | $1.35B | +2.87% | 0.00% |
| VRDN | 44.80% | $1.60B | +28.92% | 0.00% |
| ARWR | 44.51% | $2.31B | -34.44% | 0.00% |
| TWST | 44.32% | $2.42B | +74.27% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| TPST | -0.02% | $37.75M | -77.59% | 0.00% |
| UNH | -0.07% | $531.00B | +6.93% | 1.37% |
| AXS | 0.09% | $7.14B | +55.12% | 2.06% |
| SYY | -0.11% | $36.55B | +4.35% | 2.73% |
| EG | 0.13% | $15.92B | -8.98% | 2.02% |
| HIG | 0.14% | $33.87B | +51.09% | 1.60% |
| FDP | 0.15% | $1.62B | +45.67% | 2.97% |
| OCX | 0.23% | $42.93M | -36.09% | 0.00% |
| LPTH | -0.27% | $62.27M | +33.05% | 0.00% |
| WHLM | -0.27% | $17.64M | -29.34% | 0.00% |
| CMG | 0.39% | $80.02B | +33.62% | 0.00% |
| QXO | -0.47% | $6.51B | -35.95% | 0.00% |
| TW | -0.48% | $28.66B | +42.39% | 0.29% |
| KEP | 0.67% | $11.16B | +25.58% | 0.00% |
| ARC | 0.69% | $146.66M | +18.95% | 5.90% |
| RILY | 0.70% | $145.72M | -79.86% | 20.75% |
| T | 0.84% | $163.09B | +40.40% | 4.87% |
| GPRK | -0.89% | $440.00M | -9.95% | 6.37% |
| CMTL | -0.93% | $84.44M | -76.16% | 0.00% |
| BRO | 0.97% | $31.27B | +47.55% | 0.49% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CHD | -18.05% | $27.18B | +19.50% | 1.03% |
| MCK | -16.90% | $78.15B | +35.51% | 0.42% |
| CBOE | -16.87% | $21.46B | +15.84% | 1.11% |
| PULM | -15.73% | $19.83M | +202.98% | 0.00% |
| PGR | -15.69% | $149.10B | +57.29% | 0.45% |
| LMT | -15.67% | $126.40B | +18.99% | 2.36% |
| CME | -14.94% | $82.76B | +9.21% | 1.98% |
| PG | -14.58% | $402.15B | +14.14% | 2.33% |
| COR | -13.78% | $47.48B | +21.20% | 0.86% |
| GIS | -12.64% | $34.85B | -2.91% | 3.78% |
| HUSA | -11.66% | $16.69M | -11.56% | 0.00% |
| PEP | -10.47% | $215.02B | -6.60% | 3.35% |
| CCEC | -10.39% | $1.02B | +28.03% | 3.26% |
| CL | -10.28% | $76.48B | +22.25% | 2.12% |
| BTCT | -10.09% | $42.61M | +353.33% | 0.00% |
| KDP | -9.96% | $42.76B | -1.22% | 2.77% |
| WRB | -9.92% | $22.94B | +29.98% | 0.69% |
| NOC | -9.84% | $71.54B | +4.23% | 1.60% |
| ACGL | -8.44% | $36.00B | +16.84% | 0.00% |
| K | -8.23% | $27.77B | +52.50% | 2.79% |
ETF's related to ALEC
News
Yahoo
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $50 million. “Alector is in a strong cash position with more than $457 million in cash and investments. This credit facility further enhances our financial strength and provides the Company with increased strate
Finnhub
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital South San Francisco, Calif., November 14, 2024 -- Alector, Inc. , a clinical-stage biotechnology...
Yahoo
Alector (ALEC) delivered earnings and revenue surprises of 18.87% and 6.06%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer’s disease (AD), on track for 2024 Participant baseline characteristics in pivotal INFRONT-3 Phase 3 trial suggest a representative study population for testing the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation (FTD-GRN) $457.2 million in cash, cash equivalents and investments provide runway through 2026 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- A
Yahoo
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Yahoo
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.